IO-IO vs IO-TKI efficacy in metastatic kidney cancer patients: A structured systematic review over time
Benedikt Hoeh, Rocco Simone Flammia, Lukas Hohenhorst, Gabriele Sorce, Andrea Panunzio, Stefano Tappero, Zhe Tian, Fred Saad, Michele Gallucci, Alberto Briganti, Carlo Terrone, Shahrokh F. Shariat, Markus Graefen, Derya Tilki, Alessandro Antonelli, Marina Kosiba, Luis A. Kluth, Andreas Becker, Felix K.‐H. Chun, Pierre I. Karakiewicz
Topics & Concepts
MedicineNivolumabInternal medicineIpilimumabCabozantinibPembrolizumabAxitinibSunitinibRenal cell carcinomaOncologyKidney cancerHazard ratioClinical trialProgression-free survivalCancerImmunotherapyOverall survivalConfidence intervalRenal cell carcinoma treatmentBladder and Urothelial Cancer TreatmentsRenal and related cancers